Amneal Pharmaceuticals, Inc. (AMRX): Operating Cash Flow
$339.99M
Year ended 2025-12-31
$200.78M
Trailing 12 months to 2026-06-30
+73.5%
3-year compound annual growth
-2.1%
5-year compound annual growth
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $339.99M | +15.2% | 2026-02-27, From 2025-01-01 |
| 2024-12-31 | $295.10M | -14.6% | 2026-02-27, From 2024-01-01 |
| 2023-12-31 | $345.58M | +430.8% | 2026-02-27, From 2023-01-01 |
| 2022-12-31 | $65.10M | -73.1% | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | $241.82M | -36.2% | 2024-03-14, From 2021-01-01 |
| 2020-12-31 | $379.00M | n/m | 2023-03-03, From 2020-01-01 |
| 2019-12-31 | $1.71M | -99.3% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $250.23M | +6.9% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $234.19M | +103.5% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $115.06M | n/a | 2019-03-01, From 2016-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | 2025-12-31 | $339.99M | +15.2% |
| United Therapeutics Corp (UTHR) | 2025-12-31 | $1.56B | +17.6% |
| BioMarin Pharmaceutical Inc (BMRN) | 2025-12-31 | $827.99M | +44.5% |
| Alnylam Pharmaceuticals, Inc. (ALNY) | 2025-12-31 | $524.08M | n/m |
| Royalty Pharma plc (RPRX) | 2025-12-31 | $2.49B | -10.1% |
| Sarepta Therapeutics, Inc. (SRPT) | 2025-12-31 | -$205.48M | n/m |
| Perrigo Co PLC (PRGO) | 2025-12-31 | $238.50M | -34.3% |
| Jazz Pharmaceuticals plc (JAZZ) | 2025-12-31 | $1.36B | -2.9% |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $560.00M | +3.5% |
Compare AMRX, UTHR, BMRN, ALNY side by side · Screen every company in Pharmaceutical Preparations ↗